[go: up one dir, main page]

SI2121989T1 - Mutacije k-ras in terapija s protitelesi anti-egfr - Google Patents

Mutacije k-ras in terapija s protitelesi anti-egfr

Info

Publication number
SI2121989T1
SI2121989T1 SI200831191T SI200831191T SI2121989T1 SI 2121989 T1 SI2121989 T1 SI 2121989T1 SI 200831191 T SI200831191 T SI 200831191T SI 200831191 T SI200831191 T SI 200831191T SI 2121989 T1 SI2121989 T1 SI 2121989T1
Authority
SI
Slovenia
Prior art keywords
egfr antibody
antibody therapy
ras mutations
ras
mutations
Prior art date
Application number
SI200831191T
Other languages
English (en)
Other versions
SI2121989T2 (sl
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2121989(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI2121989T1 publication Critical patent/SI2121989T1/sl
Publication of SI2121989T2 publication Critical patent/SI2121989T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SI200831191T 2007-03-13 2008-03-11 Mutacije k-ras in terapija s protitelesi anti-egfr SI2121989T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13
EP08742061.8A EP2121989B2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy
PCT/US2008/003312 WO2008112269A2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy

Publications (2)

Publication Number Publication Date
SI2121989T1 true SI2121989T1 (sl) 2014-06-30
SI2121989T2 SI2121989T2 (sl) 2022-05-31

Family

ID=39689242

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831873T SI2465950T1 (sl) 2007-03-13 2008-03-11 Mutacije K-ras in terapija s protitelesi anti-EGFR
SI200831191T SI2121989T2 (sl) 2007-03-13 2008-03-11 Mutacije k-ras in terapija s protitelesi anti-egfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200831873T SI2465950T1 (sl) 2007-03-13 2008-03-11 Mutacije K-ras in terapija s protitelesi anti-EGFR

Country Status (21)

Country Link
US (3) US20080293055A1 (sl)
EP (2) EP2121989B2 (sl)
JP (1) JP2010521153A (sl)
AR (1) AR065687A1 (sl)
AU (1) AU2008226803A1 (sl)
CA (1) CA2680326A1 (sl)
CL (1) CL2008000717A1 (sl)
CY (2) CY1115333T1 (sl)
DK (2) DK2465950T3 (sl)
ES (2) ES2458626T5 (sl)
HR (2) HRP20140360T4 (sl)
HU (1) HUE033695T2 (sl)
LT (1) LT2465950T (sl)
MX (1) MX2009009787A (sl)
PE (1) PE20081880A1 (sl)
PL (2) PL2465950T3 (sl)
PT (2) PT2465950T (sl)
RS (2) RS56422B1 (sl)
SI (2) SI2465950T1 (sl)
TW (1) TW200902553A (sl)
WO (1) WO2008112269A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
PE20090690A1 (es) * 2007-03-13 2009-06-22 Amgen Inc Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
BRPI0921043A2 (pt) 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CA2796281C (en) * 2010-04-12 2016-10-11 Response Genetics, Inc. Kras primers and probes
WO2012040387A1 (en) 2010-09-24 2012-03-29 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP4036247B1 (en) 2012-09-04 2024-04-10 Guardant Health, Inc. Methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG10201707548RA (en) * 2013-03-19 2017-10-30 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
SG10201804519RA (en) 2013-12-28 2018-07-30 Guardant Health Inc Methods and systems for detecting genetic variants
EP3805404A1 (en) 2014-05-13 2021-04-14 Board of Regents, The University of Texas System Gene mutations and copy number alterations of egfr, kras and met
CN117174167A (zh) 2015-12-17 2023-12-05 夸登特健康公司 通过分析无细胞dna确定肿瘤基因拷贝数的方法
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6395486B1 (en) 1999-03-15 2002-05-28 Applera Corporation Probe/mobility modifier complexes for multiplexnucleic acid detection
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
CA2527321A1 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1733056B1 (en) 2004-03-31 2013-05-22 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
US20060088870A1 (en) * 2004-10-22 2006-04-27 Finkelstein Sydney D Topographic genotyping for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts and related conditions
BRPI0609615A2 (pt) 2005-04-01 2010-04-27 Amgen Inc métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente
JP2008535508A (ja) * 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
WO2007001868A1 (en) * 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
WO2007025044A2 (en) 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008033442A2 (en) * 2006-09-12 2008-03-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
PE20090690A1 (es) * 2007-03-13 2009-06-22 Amgen Inc Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr

Also Published As

Publication number Publication date
ES2458626T5 (es) 2022-04-29
CY1115333T1 (el) 2017-01-04
US20080293055A1 (en) 2008-11-27
US20190048423A1 (en) 2019-02-14
PL2121989T5 (pl) 2023-03-06
WO2008112269A2 (en) 2008-09-18
WO2008112269A3 (en) 2008-11-20
EP2465950A2 (en) 2012-06-20
RS56422B1 (sr) 2018-01-31
US11155876B2 (en) 2021-10-26
SI2465950T1 (sl) 2017-11-30
JP2010521153A (ja) 2010-06-24
RS53265B2 (sr) 2022-06-30
PE20081880A1 (es) 2008-12-31
HRP20140360T4 (hr) 2022-06-10
DK2465950T3 (en) 2017-10-09
PL2465950T3 (pl) 2017-12-29
PT2465950T (pt) 2017-10-17
CL2008000717A1 (es) 2008-09-22
CY1119112T1 (el) 2018-02-14
SI2121989T2 (sl) 2022-05-31
HUE033695T2 (en) 2017-12-28
RS53265B (sr) 2014-08-29
US10030270B2 (en) 2018-07-24
HRP20171509T1 (hr) 2017-11-17
PT2121989E (pt) 2014-04-30
HRP20140360T1 (hr) 2014-05-23
EP2121989A2 (en) 2009-11-25
EP2465950B1 (en) 2017-07-12
DK2121989T4 (da) 2022-06-20
LT2465950T (lt) 2017-10-10
EP2121989B2 (en) 2022-03-09
ES2458626T3 (es) 2014-05-06
ES2635051T3 (es) 2017-10-02
DK2121989T3 (da) 2014-04-28
EP2121989B1 (en) 2014-01-22
MX2009009787A (es) 2009-09-22
AU2008226803A1 (en) 2008-09-18
EP2465950A3 (en) 2013-03-13
TW200902553A (en) 2009-01-16
CA2680326A1 (en) 2008-09-18
AR065687A1 (es) 2009-06-24
PL2121989T3 (pl) 2014-07-31
US20120264129A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
PT2465950T (pt) Mutações de k-ras e terapia de anticorpo anti-egfr
PL2412828T3 (pl) Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
GB0803018D0 (en) Therapeutic compounds and their use
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
GB0804685D0 (en) Therapeutic compounds and their use
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB2460181B (en) Depsipeptides and their therapeutic use
GB2460178B (en) Depsipeptides and their therapeutic use
EP2142648A4 (en) SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
IL206420A0 (en) Azetidine derivatives, their preparation and their application in therapy
GB0812913D0 (en) Therapeutic compounds and their use
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB2460180B (en) Depsipeptides and their therapeutic use
GB0802128D0 (en) Therapeutic compounds and their use
HK1139182A (en) K-ras and b-raf mutations and anti-egfr antibody therapy
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT